Genflow: potential multi-billion--dollar market for companion animal longevity21 Apr 2026 07:09
The Genflow Biosciences (LSE: GENF) canine longevity trial (GF-1004) is considered highly significant because it is the world's first gene therapy clinical trial targeting aging in dogs using SIRT6-centenarian gene therapy. As of April 2026, the trial has reported encouraging safety, efficacy, and duration of effect, bridging the gap between preclinical research and potential commercial veterinary applications, while acting as a stepping stone for human longevity treatments.
Here is why the SOG (SIRT6 On Dog) trial is significant:
Positive Safety and Preliminary Efficacy: The trial, which began in March 2025 on 28 dogs aged 10 and older, reported no adverse events during the dosing phase. Preliminary interim results have shown positive signals in reducing frailty, preserving muscle mass, and improving overall health metrics.
Sustained "Persistence of Effect": A major breakthrough reported in April 2026 was that the therapeutic benefits in dogs continued for months after the treatment was stopped, showing a durable impact rather than a requirement for chronic treatment.
Targeting the "Centenarian" SIRT6 Gene: The therapy uses a variant of the SIRT6 gene found in long-lived humans, aiming to increase DNA repair and improve metabolic regulation, which both degrade with age.
Commercial Potential in Animal Health: The successful results enable Genflow to move toward licensing agreements with larger animal health companies, targeting the multibillion-dollar market for companion animal longevity.
A "Bridge" to Human Trials: The data generated from this trial will inform and support Genflow's efforts to develop similar gene-based treatments for age-related diseases in humans, specifically MASH (Metabolic Dysfunction-Associated Steatohepatitis).
The trial is slated for full completion in July 2026, with further analysis on biological age, muscle histology, and long-term effects ongoing.
Sign In
Follow the stocks
